Newsroom | 96913 results

ORLANDO, Fla.--(BUSINESS WIRE)--OutcomeRx Insurance Management Services, LLC today announced the launch of CGT Solutions Stop-Loss, a stand-alone medical stop-loss insurance product that reimburses covered expenses on qualified claims for Gene and CAR T-cell therapies for group health plans and their coordinating Stop-Loss carrier. This innovative solution, in addition to reimbursement for certain FDA approved Prescription Drugs, uniquely reimburses administration of the Prescription Drug and t...

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--  Los nuevos análisis de datos presentados en Heart Failure 2026 demuestran un beneficio clínico importante y consistente de vutrisiran como opción terapéutica de primera línea en todas las poblaciones de pacientes con ATTR-CM, incluyendo aquellos con una carga elevada de la enfermedad Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la empresa líder en terapias basadas en el ARNi, ha anunciado hoy nuevos análisis del estudio HELIOS-B de fase III sobre vu...

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--  Le nuove analisi dei dati presentate al congresso Heart Failure 2026 dimostrano un beneficio clinico notevole e costante di vutrisiran come opzione terapeutica di prima linea in tutte le popolazioni di pazienti affetti da ATTR-CM, compresi quelli con un carico di malattia elevato Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), l'azienda leader nel settore delle terapie basate sull'RNAi ha annunciato oggi i risultati di nuove analisi condotte nell'ambit...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--  Nieuwe gegevensanalyses die zijn gepresenteerd tijdens Heart Failure 2026 tonen een robuust en consistent klinisch voordeel aan van vutrisiran als eerstelijnsbehandelingsoptie bij alle patiëntengroepen met ATTR-CM, inclusief patiënten met een hoge ziektelast Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), het toonaangevende bedrijf op het gebied van RNAi-therapieën, heeft vandaag nieuwe analyses bekendgemaakt van de HELIOS-B fase 3-studie naar vutrisiran bij p...

WILLIAMSON, W.Va.--(BUSINESS WIRE)--Today marks the official launch of Halo340B (www.halo340b.com), a next-generation AI technology platform designed to transform how healthcare organizations manage the 340B Drug Pricing Program. By delivering a seamless, automated solution, Halo340B eliminates the complexities of program compliance while uncovering missed opportunities to significantly increase revenue for covered entities. For years, covered entities—including health centers, hospitals, rural...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Skylark Bio, a biotechnology company developing targeted genetic medicines for hearing loss, today announced that it will present new preclinical data for SKY-PEN, its Pendrin gene therapy program in development for SLC26A4-related hearing loss, at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting. “The SKY-PEN data we’re sharing at ASGCT, together with data supporting the IND filing for our lead program SKY-GJB2, reflect important pr...

TROY, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCID: ZIVO) ("ZIVO" or the "Company") announced today that it is transitioning its common stock to quotation on the OTCID marketplace. Zivo Bioscience began trading on OTCID as of Monday, May 11, 2026. Transitioning to OTCID is a common step for companies seeking to maintain public trading while aligning with a marketplace that offers streamlined reporting requirements, improved flexibility, and continued visibility for investors. Companies...

CLEARWATER, Fla.--(BUSINESS WIRE)--PriceMDs today announced the launch of a new API integration platform designed to help pharmacy benefit managers (PBMs), third-party administrators (TPAs), and healthcare organizations streamline prescription sourcing and specialty medication management within their existing workflows. The platform connects pricing, patient onboarding, regulatory documentation, shipment tracking, and claims reporting into a single integration, reducing the need for manual proc...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Vast Therapeutics, a clinical-stage life science company developing nitric oxide-based medicines for serious lung diseases, will present a late-breaking poster presentation demonstrating safety and pharmacokinetic data from the Phase 1 study of its inhaled drug candidate ALX1 at the American Thoracic Society (ATS) 2026 International Conference. ALX1 contains a first-in-class, small molecule nitric oxide prodrug designed to provide dual-action anti-inflammator...

ANN ARBOR, Mich.--(BUSINESS WIRE)--North American companies ordered 9,055 robots valued at $543 million in the first quarter of 2026, according to new data released by the Association for Advancing Automation (A3). Compared to the first quarter of 2025, this represents a 0.1% decrease in units ordered and a 6.4% decline in revenue1. While unit orders were essentially flat, order revenue declined year over year, driven largely by a cyclical decline in Automotive OEM orders, which fell 35.1% in u...